Through
12/30
A preclinical Penn Medicine study explains the previously observed anti-cancer effect of the common anesthetic drug.
A Projects for Progress team in the Abramson Cancer Center continues to work with the West Philadelphia community to bring cancer screenings out of clinical settings.
The studies on AAV-based gene therapies in non-human primates suggest that integration into human DNA is unlikely to drive cancer mutations.
Ben Stanger, the Hanna Wise Professor in Cancer Research and professor of medicine and cell and developmental biology, discusses his research and publishing his first book, ‘From One Cell: A Journey into Life’s Origins and the Future of Medicine.’
Researchers at Penn Medicine have developed a first-ever tool that gives a real-time assessment of tumors to provide less uncertainty for patients worrying between scans.
An interdisciplinary team of researchers in the School of Engineering and Applied Science, Perelman School of Medicine, and School of Arts & Sciences has developed a technique that allows for characterization of both individual carrier and cargo for clinically important molecules.
Researchers from the School of Veterinary Medicine and Perelman School of Medicine have shown that invariant natural killer T cells from a healthy donor can persist in MHC-mismatched canines, demonstrating a reliable platform to inform human clinical trials.
Penn researchers uncover a new way to target solid tumors. Using CAR T cells to remove cancer-associated fibroblasts surrounding pancreatic tumors allows T cells to infiltrate and attack the tumor cells.
Researchers from the School of Veterinary Medicine have shown that an enzyme that suppresses early-stage colorectal cancer switches to become an oncogene as the cancer progresses.
Researchers at Penn Medicine have demonstrated a new potential treatment using CAR T cell therapy using a CRISPR base-editing to develop a method called “epitope editing.”
Carl June of the Perelman School of Medicine praises New Zealand research into a new CAR T-cell cancer treatment for patients with blood cancer.
FULL STORY →
Emily Whitehead of Philipsburg, Pennsylvania, the first child cured of leukemia with CAR-T cancer therapy, has returned to Penn as a first-year in the College of Arts and Sciences.
FULL STORY →
Research by Bo Li of the Perelman School of Medicine finds that cancer cells can use mitochondria to sap energy from T cells, resisting treatment and evading the body’s defenses.
FULL STORY →
Research from Michael Mitchell of the School of Engineering and Applied Science has developed a new method to stop cytokine release during CAR T cell therapy, preventing some of its more dangerous side effects.
FULL STORY →
Carl June of the Perelman School of Medicine has been awarded a $3 million Breakthrough Prize in life sciences for developing CAR-T therapy to treat cancer, with remarks from President Liz Magill.
FULL STORY →
Carl June of the Perelman School of Medicine was awarded a $3 million Breakthrough Prize in life sciences for developing CAR-T therapy to treat cancer.
FULL STORY →